The use of Dotrecogin alpha has been suggested to reduce neuronal damage in human sepsis, even if its effect has been evaluated by measuring of serum S100B, which is not a reliable marker of SAE, like previously reported (25). This evidence concerns the gene S100B and Sepsis.